{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:08Z","timestamp":1791593828111,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jns.2013.10.043","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T03:17:27Z","timestamp":1383707847000},"page":"39-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Maintenance IVIg therapy in myasthenia gravis does not affect disease activity"],"prefix":"10.1016","volume":"338","author":[{"given":"M.A.","family":"Hellmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mosberg-Galili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-9783","authenticated-orcid":false,"given":"I.","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2013.10.043_bb0005","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1196\/annals.1254.060","article-title":"Treatment principles in the management of autoimmune myasthenia gravis","volume":"998","author":"Richman","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jns.2013.10.043_bb0010","first-page":"CD005224","article-title":"Immunosuppressive agents for myasthenia gravis","volume":"4","author":"Hart","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jns.2013.10.043_bb0015","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"8232","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2013.10.043_bb0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/TCRM.S14015","article-title":"Current and emerging treatments for the management of myasthenia gravis","volume":"7","author":"Sathasivam","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jns.2013.10.043_bb0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00002826-200105000-00010","article-title":"The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis","volume":"24","author":"Hilkevich","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jns.2013.10.043_bb0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.0.CO;2-O","article-title":"Immunoglobulin treatment in refractory myasthenia gravis","volume":"23","author":"Achiron","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2013.10.043_bb0035","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jns.2013.10.043_bb0040","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.22327","article-title":"Estimated cost of treating myasthenia gravis in an insured U.S. population","volume":"45","author":"Guptill","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2013.10.043_bb0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.10.043_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/aos\/1176344552","article-title":"Bootstrap methods: another look at the jackknife","volume":"7","author":"Efron","year":"1979","journal-title":"Ann Stat"},{"key":"10.1016\/j.jns.2013.10.043_bb0055","first-page":"440","article-title":"Intravenous immunoglobulin in neurological disease: a specialist review","volume":"72","author":"Wiles","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jns.2013.10.043_bb0060","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2013.10.043_bb0065","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin \u2014 a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2013.10.043_bb0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis \u2014 a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.10.043_bb0075","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis","volume":"25","author":"Ronager","year":"2001","journal-title":"Artif Organs"},{"key":"10.1016\/j.jns.2013.10.043_bb0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mus.10224","article-title":"Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis","volume":"26","author":"Wolfe","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2013.10.043_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0303-8467(02)00017-3","article-title":"Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis","volume":"105","author":"Wegner","year":"2002","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jns.2013.10.043_bb0090","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1749-6632.1981.tb33766.x","article-title":"Observations of the natural history of myasthenia gravis and the effect of thymectomy","volume":"377","author":"Oosterhuis","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jns.2013.10.043_bb0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.10.043_bb0100","first-page":"CD002828","article-title":"Corticosteroids for myasthenia gravis","volume":"2","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jns.2013.10.043_bb0105","first-page":"765","article-title":"High-dose immunosuppressive therapy in generalised myasthenia gravis \u2014 a 2-year follow-up study","volume":"91","author":"Heckmann","year":"2001","journal-title":"S Afr Med J"},{"key":"10.1016\/j.jns.2013.10.043_bb0110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ana.410170304","article-title":"Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine","volume":"17","author":"Hohlfeld","year":"1985","journal-title":"Ann Neurol"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X13030050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X13030050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:43:36Z","timestamp":1758383016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X13030050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":22,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0022510X13030050"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2013.10.043","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance IVIg therapy in myasthenia gravis does not affect disease activity","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2013.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}